Cidara Therapeutics, Inc.
CDTX
$19.44
$0.261.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.28M | 4.03M | 13.25M | 18.04M | 23.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.28M | 4.03M | 13.25M | 18.04M | 23.28M |
| Cost of Revenue | 71.88M | 33.02M | 30.97M | 32.97M | 36.76M |
| Gross Profit | -70.60M | -28.98M | -17.72M | -14.94M | -13.48M |
| SG&A Expenses | 20.62M | 16.75M | 15.09M | 13.52M | 13.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.49M | 49.77M | 46.06M | 46.50M | 50.34M |
| Operating Income | -91.22M | -45.74M | -32.81M | -28.46M | -27.06M |
| Income Before Tax | -170.29M | -126.10M | -114.42M | -26.33M | -25.07M |
| Income Tax Expenses | -- | 7.00K | -25.00K | 15.00K | 15.00K |
| Earnings from Continuing Operations | -170.29 | -126.10 | -114.39 | -26.35 | -25.08 |
| Earnings from Discontinued Operations | 464.00K | 5.37M | 536.00K | -9.92M | 2.15M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -169.83M | -120.73M | -113.86M | -36.27M | -22.93M |
| EBIT | -91.22M | -45.74M | -32.81M | -28.46M | -27.06M |
| EBITDA | -91.07M | -45.59M | -32.68M | -28.34M | -26.95M |
| EPS Basic | -30.09 | -25.42 | -24.99 | -8.03 | -4.99 |
| Normalized Basic EPS | -7.26 | -5.02 | -4.07 | -3.64 | -3.61 |
| EPS Diluted | -30.09 | -25.43 | -25.00 | -8.03 | -4.99 |
| Normalized Diluted EPS | -7.26 | -5.02 | -4.07 | -3.64 | -3.61 |
| Average Basic Shares Outstanding | 25.36M | 20.16M | 18.14M | 18.08M | 17.48M |
| Average Diluted Shares Outstanding | 25.36M | 20.16M | 18.14M | 18.08M | 17.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |